1Rycroft CE, Heyes A, Lanza L, et al. Epidemiology of chronicobstructive pulmonary disease: a literature review[J] . Int J ChronObstruct Pulmon Dis, 2012, 7: 457-494.
8McGarvey LP,John M,Anderson JA, et al. Ascertainment of cause- specific mortality in COPD:operations of the TORCH Clinical End- point Committee. Thorax,2007,62 ( 5 ) :411-415.
9Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest, 2005,128(6) :3810-3816.
10CeUi BR,Cote CG, Matin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic ob- structive pulmonary disease. N Engl J Med, 2004,350 (10) :1005- 1012.
2Ulrik CS.Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.Int J Chron Obstruct Pulmon Dis. 2014,9(1):331-8.
3Frampton JE.QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease.Drugs. 2014,74(4):465-88.
